Previous

Immune-Onc Therapeutics Awarded $2.14 Million National Cancer Institute SBIR Grant to Support Development of IO-202, a First-in-Class Antibody Targeting LILRB4
Next

Immune-Onc Therapeutics IND Application for First-In-Human Trial of IO-202, a Novel Antibody for the Treatment of Acute Myeloid Leukemia, Receives FDA Clearance